about
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trialsRisk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical TrialsEverolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data.Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastomaSunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapyIncidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy.Neoadjuvant therapy in pancreatic cancer: an emerging strategyNatural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives.Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis surveyBone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patientsPrognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis.Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents.Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma.Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective AnalysisImpact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomyProtracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II studyPre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinomaPrognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapyRisk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma.Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: When is the revolution coming?TRP channels: new potential therapeutic approaches in CNS neuropathies.Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer.Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside.Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review.Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma.Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma.Chromium exposure and germinal embryonal carcinoma: first two cases and review of the literature.Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives.Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview.Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature.
P50
Q26822790-4A5DD4BA-33E6-46B7-9166-B42D683F0D8DQ28551983-ED3AA77F-313C-4905-A086-8FB443403518Q30845230-99B10190-8B4C-4A3D-AA50-9926CF43A9ABQ33406919-309EA1FB-AA28-4BB2-8FAB-4E559B791202Q33424769-E61F1F31-DB48-4027-BA0B-1CCCD8C8B631Q33618900-D59AD5CC-4A5D-471B-98D7-0A84BB62B53EQ33887946-21845E87-68E8-4AA9-BCAF-F535EB282D27Q33914671-08A03424-A797-4046-B9FD-16E4428C1DB5Q34109952-2AB4AF4D-3B23-4898-BFE3-DA0C3B4D17B0Q34351372-582F3BC0-6ED4-4BD6-A5DC-F08DF4986E4EQ34660799-55459B20-3492-45A0-BC3B-2FB6B506F934Q35080143-49930CA1-F405-42CA-A9F2-D2D7AD1BA4D3Q35083485-ABB05722-25F5-43E8-89BA-550E1E4963E2Q35464515-219E42E5-6DE1-4BBD-BFD2-B5DD3779E6F8Q35595696-15AB3474-C3A4-4804-B525-F7ECA3999580Q35796302-894FECB5-CEFA-4FF1-949D-EDDA2501D203Q35906161-0866AFBC-F5D7-486E-93A6-AABCCE80861FQ35956248-E86C8676-9021-49D7-A261-1D394ADDDF68Q35985736-139EBC73-C9D6-4D90-AE99-AEBB7A13D3F8Q36326385-39941D37-6AC8-4AD7-9A8B-9C0ACAC0805CQ36423867-CE3D03BA-ED93-4468-BF7A-52C6BE102655Q37214300-F4B78FF2-FADB-4484-8C12-089A9E4D503AQ37295840-87307333-CCA8-4BE5-8A2B-FDBBDC0DD7ECQ37362945-99B06E32-EA70-4DA4-B160-BE7EB221C7BCQ37688103-715C1A78-6ADD-484E-B36D-1BA3F41442C7Q38063351-A13C4774-7706-4CD8-970E-34444ED1B3D5Q38087368-70E4C5C3-B516-4679-AA61-73C7DBE2062EQ38110796-513C0969-FD5C-4849-9554-7D0319B0534BQ38144490-3737AAF5-7848-4E6E-939C-24D2F2F5DBFFQ38171327-3F201146-B6C3-47C4-B2C1-5A160405A83DQ38172697-7592C085-EBC0-4CF9-94C7-5BEA052549BAQ38177768-D6632475-3098-4212-B4ED-57AFACDE1D00Q38242643-0A64CA0F-4E5A-42B4-9361-22FFD24EB009Q38260884-8327A704-8F33-45AA-BD97-F0DC400A5AB1Q38271395-A07466AB-37AC-49D0-966F-BC1841CA0A4AQ38275758-6694BF75-4988-4105-BC93-B34CB3B10B0EQ38282194-C5924B80-9DD6-40BC-A353-EA87723E578FQ38312045-F0C540A6-270A-4886-83F2-5AEC80B881E1Q38317515-9578A68F-DF41-4F1C-B415-BBFC1AE9F4C8Q38334611-6967F9FA-6ED9-4A72-9EDA-02D9408E00ED
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Matteo Santoni
@ast
Matteo Santoni
@en
Matteo Santoni
@es
Matteo Santoni
@nl
type
label
Matteo Santoni
@ast
Matteo Santoni
@en
Matteo Santoni
@es
Matteo Santoni
@nl
prefLabel
Matteo Santoni
@ast
Matteo Santoni
@en
Matteo Santoni
@es
Matteo Santoni
@nl
P106
P1153
36090383100
P31
P496
0000-0001-7340-6173